Previous Close | 2.4200 |
Open | 2.3860 |
Bid | 2.3300 x 4000 |
Ask | 2.6000 x 3000 |
Day's Range | 2.3200 - 2.4400 |
52 Week Range | 1.1300 - 4.0400 |
Volume | |
Avg. Volume | 115,400 |
Market Cap | 58.261M |
Beta (5Y Monthly) | 0.83 |
PE Ratio (TTM) | 8.16 |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Combines mesenchymal stem-cell-based product, with Kurve’s intranasal drug delivery technologyGERMANTOWN, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, and Kurve Therapeutics, a next-generation medtech and drug formulation company, today announced positive preclinical study results for intranasal administration of a cell-based oncolytic virus bearing pr
Secures up to $50 Million of Funding from Metalmark Capital Partners Expected to Accelerate Rollout of Point-of-Care Services Reduces operating expenses by 49% to achieve nearly breakeven income from operation for the third quarter of 2022 Orgenesis to Host Conference Call on Friday, November 11, 2022 at 8:00 AM Eastern Time GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potentia
GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company’s corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 fo